The Genetic Basis for Vulnerability to Substance Abuse
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00247819|
Recruitment Status : Completed
First Posted : November 2, 2005
Last Update Posted : January 12, 2017
|Condition or disease||Intervention/treatment|
|Substance Abuse||Procedure: Blood draw|
Dopamine (DA), a neurotransmitter helping to mediate reward and reinforcement, has been putatively linked to the development of substance abuse, alcohol abuse, and alcoholism. Identification of specific vulnerability-association alleles for receptors, other molecules within the reward mediating system, and other genes that may predispose individuals to the development of such disorders is the goal of the study.
This investigation will help elucidate the genetic underpinnings of substance abuse, potentially leading to the improved methods to diagnose those at risk and to help develop better therapeutic interventions.
|Study Type :||Observational|
|Estimated Enrollment :||8000 participants|
|Official Title:||Allelic Linkage in Substance Abuse|
|Study Start Date :||August 1992|
|Actual Primary Completion Date :||February 2006|
|Actual Study Completion Date :||February 2006|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00247819
|United States, Maryland|
|National Institute on Drug Abuse|
|Baltimore, Maryland, United States, 21224|
|Principal Investigator:||George Uhl, M.D., Ph.D.||National Institute on Drug Abuse (NIDA)|